ASCO's Guideline Rapid Recommendation Update for ESR1 Mutation Testing
Elacestrant improved progression-free survival in HR-positive, HER2-negative advanced breast cancer patients with ESR1 mutations, leading to updated ASCO guidelines recommending routine ESR1 mutation testing at progression. Blood-based ctDNA testing is preferred for its sensitivity and safety. Other treatments include endocrine therapy with targeted agents for non-ESR1 mutation cases.
Reference News
Elacestrant improved progression-free survival in HR-positive, HER2-negative advanced breast cancer patients with ESR1 mutations, leading to updated ASCO guidelines recommending routine ESR1 mutation testing at progression. Blood-based ctDNA testing is preferred for its sensitivity and safety. Other treatments include endocrine therapy with targeted agents for non-ESR1 mutation cases.